Patents Assigned to Shionogi & Co., Ltd.
  • Publication number: 20210317125
    Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.
    Type: Application
    Filed: June 16, 2021
    Publication date: October 14, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Koji MASUDA, Shuichi SUGIYAMA, Toru YAMADA, Eiichi KOJIMA, Tomoyuki OGAWA, Naotake KOBAYASHI, Hiroyuki KAI
  • Patent number: 11136411
    Abstract: Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: October 5, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Shoichi Naito, Hiroaki Aino, Etsuo Nakamura, Sunao Imai, Shoji Yamane
  • Patent number: 11135217
    Abstract: The present invention offers the manufacturing method of the solid formulation wherein the standard deviation of the active ingredient content in the solid formulation becomes 5% or less by mixing the excipients which have a median particle size of 15 or more times, preferably 20 times or more to the median particle size of an active ingredient.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: October 5, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Akira Mashimo, Shunji Ichio
  • Publication number: 20210292321
    Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.
    Type: Application
    Filed: June 29, 2019
    Publication date: September 23, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Shionogi & Co., Ltd.
    Inventors: Akihiro ISHII, Akihiko SATO, Makoto KAWAI, Yoshiyuki TAODA
  • Publication number: 20210292283
    Abstract: A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p 1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 27, 2021
    Publication date: September 23, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Satoru TANAKA, Tomoyuki OGAWA, Hiroyuki KAI, Yuki OGATA, Keiichiro HIRAI, Noriyuki KUROSE, Yasuhiko FUJII
  • Patent number: 11124486
    Abstract: A compound represented by Formula (I): wherein or the like, Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like, Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 21, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tomoyuki Ogawa, Hiroyuki Kai, Keiichiro Hirai
  • Patent number: 11116727
    Abstract: The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 14, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Akira Mashimo, Shunji Ichio
  • Publication number: 20210230187
    Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 29, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Setsuya SHIBAHARA, Nobuaki FUKUI, Toshikatsu MAKI, Kosuke ANAN
  • Publication number: 20210221876
    Abstract: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 22, 2021
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Tatsuya TAKAHASHI, Mai YOSHIKAWA, Sosuke YONEDA, Junji ONODA, Etsuo NAKAMURA, Tsuguo MIYAUCHI, Toshiyuki ASAKI, Erika KASAI
  • Patent number: 11066409
    Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 20, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Koji Masuda, Shuichi Sugiyama, Toru Yamada, Eiichi Kojima, Tomoyuki Ogawa, Naotake Kobayashi, Hiroyuki Kai
  • Patent number: 11040048
    Abstract: A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4 is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A are each independently hydrogen, halogen, alkyl, or the like; R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R1 is or the like, is combined
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 22, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takao Shishido, Takeshi Noshi, Atsuko Yamamoto, Mitsutaka Kitano
  • Publication number: 20210172964
    Abstract: A reference standard set for BNP measurement, including a plurality of reference standards including BNP-32 and proBNP, wherein the ratio BNP-32/proBNP (mole ratio) differs between the reference standards, and when a reference standard having a high mole ratio and a reference standard having a low mole ratio are compared, the BNP concentration, which is the sum total of the BNP-32 concentration and the proBNP concentration, is lower in the reference standard having a high mole ratio than in the reference standard having a low mole ratio.
    Type: Application
    Filed: December 28, 2018
    Publication date: June 10, 2021
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Norio OTA, Keiichi MASUTA
  • Publication number: 20210163552
    Abstract: A peptide which can be utilized as an active ingredient of a composition for use in stimulation of migration of PDGFR?-positive cells, a composition for use in recruitment of bone marrow mesenchymal stem cells from bone marrow to peripheral blood, a composition for use in regeneration of tissues, or a composition for use in stimulation of migration of bone marrow-derived stromal cells is provided.
    Type: Application
    Filed: April 24, 2018
    Publication date: June 3, 2021
    Applicants: SHIONOGI & CO., LTD., StemRIM Inc.
    Inventors: Yoichiro NIHASHI, Tomoyuki KAWACHI, Yukiko YAMATSU, Masataka FUMOTO, Takehiko YAMAZAKI
  • Publication number: 20210155622
    Abstract: The present invention provides a compound represented by the following formula (I): wherein, ring A is a substituted or unsubstituted non-aromatic heterocycle; ring C is a benzene ring or the like; Q is a 5-membered aromatic heterocycle or the like; each R1 is independently halogen or the like; L is substituted or unsubstituted alkylene; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Application
    Filed: May 30, 2019
    Publication date: May 27, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventor: Yoshiyuki TAODA
  • Publication number: 20210145753
    Abstract: The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 20, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Akira MASHIMO, Shunji ICHIO, Yoshinori TAMURA, Kouichi NOGUCHI
  • Patent number: 11008320
    Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: May 18, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Akira Yukimasa, Kazuya Kano, Kenichiroh Nakamura, Motohiro Fujiu, Hiroki Yamaguchi
  • Publication number: 20210122751
    Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Application
    Filed: May 30, 2019
    Publication date: April 29, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshiyuki TAODA, Yuto UNOH
  • Publication number: 20210115148
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Application
    Filed: December 28, 2020
    Publication date: April 22, 2021
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Publication number: 20210106589
    Abstract: The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 15, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Naoya MIZUTANI, Masayuki MORIMOTO, Maki OKABE, Masaaki ITO, Go KIMURA
  • Patent number: 10952968
    Abstract: The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 23, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Akira Mashimo, Shunji Ichio, Yoshinori Tamura, Kouichi Noguchi